A Phase 3 interventional study of Lepodisiran Sodium and Placebo in Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Lp(a), sponsored by Eli Lilly and Company. Active, not recruiting at 928 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Atherosclerosis by Eli Lilly and Company — 5 open to participants now, 7 under way, 4 of them phase 3. Atherosclerosis · Eli Lilly and Company.
Among the 10 studies in Atherosclerosis by Eli Lilly and Company, this one is one of 3 that started in 2024, is one of 4 in phase 3, and was the 5th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 225 are open to participants now.
Browse Atherosclerosis studies →5 of the 10 studies in Atherosclerosis by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Verve Therapeutics, Inc. · Sites in United States
Ages 18–70
Eli Lilly and Company · Sites in United States, Argentina, Japan and 1 more country
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, Czechia and 4 more countries
Ages 45–80
Eli Lilly and Company · Sites in United States, Argentina, Australia and 25 more countries
Ages 18+
Verve Therapeutics, Inc. · Sites in New Zealand, United Kingdom
Ages 18+
By country, each count listing its studies:
Of the 161 Atherosclerosis studies recruiting now, 84 (52%) set no upper age limit and 33 (20%) stop at 75 or younger; 16 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 17,300 is above the median of 100 across 880 interventional studies indexed under Atherosclerosis.
Median enrollment 252 across the 9 interventional studies, 116 across the 1 observational. Of the 3 that completed or were terminated, 2 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
1 of the studies in Atherosclerosis by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07783802Eli Lilly and CompanyA Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Atherosclerosis by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin). Approximately 1700 additional participants will be enrolled in an addendum to explore Lp(a) lowering with an alternative dosing schema.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meet criteria of either 2a or 2b:
2a: Individuals 18 years of age or older with established atherosclerotic cardiovascular disease (ASCVD) with an event or revascularization.
2b: Individuals 55 years of age or older who are at risk for a first cardiovascular (CV) event and either: Documented coronary artery disease (CAD), carotid stenosis, or peripheral artery disease (PAD) without history of event or revascularization; known familial hypercholesteremia; or a combination of high-risk factors.
Exclusion Criteria:
Have severe renal failure, defined as
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lepodisiran sodium administered subcutaneously (SC).
Drug: Lepodisiran Sodium
Placebo administered SC.
Drug: Placebo
Administered SC
Also known as: LY3819469
Administered SC
Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)-4 Composite Endpoint
Time to first event in a MACE-4 composite endpoint, comprised of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, and urgent coronary revascularization.
Time frame: Baseline up to End of Study (About 4.5 Years)
Change from Baseline in Lipoprotein(a) [Lp(a)] at Week 4
Change from Baseline in Lp(a)
Time frame: Baseline, Week 4
Time to First Occurrence of Any of the Component of MACE-3 Composite Endpoint
Time to first occurrence MACE-3
Time frame: Baseline up to End of Study (About 4.5 Years)
Time to First Occurrence of Fatal or Non-Fatal Myocardial Infarction
Time to first occurrence of fatal or non-fatal myocardial infarction.
Time frame: Baseline up to End of Study (About 4.5 Years)
Time to Cardiovascular Death
Time to cardiovascular death.
Time frame: Baseline up to End of Study (About 4.5 Years)
Time to Occurrence of All-Cause Death
Time to occurrence of all-cause death
Time frame: Baseline up to End of Study (About 4.5 Years)
Time to First Occurrence of Any Component of the MACE-4 Composite Endpoint (In the Population with Established ASCVD and CV Event, or Revascularization)
Time to first occurrence of any component of the MACE-4 composite endpoint.
Time frame: Baseline up to End of Study (About 4.5 Years)
Time to First Occurrence of any Component of the MACE-4 Composite Endpoint (In the Population At Risk for First CV event)
Time to first occurrence of any component of the MACE-4 composite endpoint.
Time frame: Baseline up to End of Study (About 4.5 Years)
Time to First Occurrence of any Component of the MACE-4 Composite Endpoint (In the Population with Lp(a) ≥ 200 nmol/L)
Time to first occurrence of any component of the MACE-4 composite endpoint.
Time frame: Baseline up to End of Study (About 4.5 Years)
Time to First Occurrence of Any Component of MACE-3 + MALE Composite Endpoint
Time to first occurrence of any component of MACE-3 + MALE composite endpoint.
Time frame: Baseline up to End of Study (About 4.5 Years)
Time to First Occurrence of Any Component of Coronary MACE-3 Composite Endpoint
Time to first Occurrence of any component of coronary MACE-3 composite endpoint.
Time frame: Baseline up to End of Study (About 4.5 Years)
Showing the first 100 of 928 sites across 28 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Started Mar 2024 (actual). Primary completion is estimated for Mar 2029, 60 months after the start.
Of 36 industry-sponsored phase 3 interventional studies under Atherosclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's planned 60 months is above that.
Counting every sponsor, half of 53 studies reached it within 35 months; a quarter within 21 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.